Pharma gaining ground

The global market for therapeutic eye drugs is predicted to grow in 2014, and a number of new compounds are in the pipeline for treatments such as glaucoma and dry eye syndrome.  

In the UK, treatments such as Eylea (for wet AMD and RVO-related macular oedema) and Lucentis (for myopic CNV) received recommendations from NICE for use on the NHS.  

Changes to policy means that this year Scottish optometrists – registered as independent prescribers – are able to prescribe them on the NHS. 




0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply